Outset Medical (NASDAQ:OM) Rating Lowered to “Sell” at Wall Street Zen

Outset Medical (NASDAQ:OM) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

OM has been the topic of several other reports. BTIG Research decreased their target price on shares of Outset Medical from $39.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. Stifel Nicolaus set a $14.00 price target on shares of Outset Medical and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research note on Wednesday. Finally, Royal Bank Of Canada cut their target price on Outset Medical from $22.00 to $17.00 and set a “sector perform” rating for the company in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Outset Medical Stock Down 3.4%

Shares of OM stock opened at $4.29 on Friday. Outset Medical has a one year low of $4.22 and a one year high of $25.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77. The stock has a fifty day moving average price of $12.35 and a 200 day moving average price of $15.48. The stock has a market cap of $77.86 million, a P/E ratio of -0.33 and a beta of 2.14.

Hedge Funds Weigh In On Outset Medical

A number of institutional investors and hedge funds have recently bought and sold shares of OM. Legal & General Group Plc acquired a new stake in shares of Outset Medical in the second quarter valued at $34,000. Ameritas Investment Partners Inc. bought a new stake in Outset Medical during the 2nd quarter worth about $35,000. BNP Paribas Financial Markets grew its holdings in Outset Medical by 7,013.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after acquiring an additional 2,034 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in Outset Medical in the 2nd quarter valued at about $78,000. Finally, New York State Common Retirement Fund bought a new position in shares of Outset Medical in the second quarter worth about $108,000.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.